Anemia inflamatoria: fisiopatología, diagnóstico y tratamiento / Inflammatory anemia: phisiopathology, diagnosis and treatment / Anemia inflamatória: fisiopatologia, diagnóstico e tratamento

La anemia de la Inflamación (AI) es considerada la segunda causa más frecuente de anemia a nivel mundial después de la deficiencia de hierro. Se observa comúnmente en infecciones crónicas, tumores, traumas, y desórdenes inflamatorios. La AI es típicamente normocítica normocrómica usualmente moderada y se produce por una hipoferremia como resultado del secuestro de hierro en el sistema retículo endotelial, de la reducción de la eritropoyesis y de la inhibición de la absorción del hierro en intestino. La patogenia de la AI está mediada por citoquinas inflamatorias y hepcidina, péptido producido en el hígado, que regulan la homeostasis del hierro, actúan suprimiendo la eritropoyesis, y la vida media de los eritrocitos se encuentra ligeramente acortada. Los métodos diagnósticos de rutina que se describen en esta revisión pueden ser de utilidad, pero quedará un grupo de estados anémicos con alta sospecha de AI que no podrán ser fácilmente clasificados. Recientemente se han desarrollado inmunoensayos para determinar hepcidina y citoquinas inflamatorias que podrán colaborar, en un futuro, para un diagnóstico correcto. Existen actualmente modelos experimentales de AI en ratones, los cuales podrían ser útiles para evaluar diferentes tratamientos. En este sentido, los inhibidores de la hepcidina y diversos moduladores inflamatorios aparecen como terapias prometedoras.

Anemia da inflamação (AI) é considerada a segunda causa mais comum de anemia em todo o mundo após a deficiência de ferro. É geralmente observada em infecções crônicas, tumores, traumas e distúrbios inflamatórios. A AI é tipicamente normocítica normocrômica comumente moderada e ocorre por uma hipoferremia como resultado do sequestro de ferro no sistema retículo endotelial, da redução da eritropoiese e da inibição da absorção do ferro no intestino. A patogenia da AI é mediada por citocinas inflamatórias e hepcidina, peptídeo produzido no fígado, que regulam a homeostase do ferro, agem suprimindo a eritropoiese e a meia-vida dos eritrócitos é levemente diminuída. Os métodos de diagnóstico de rotina descritos nesta revisão podem ser úteis, mas ficará um grupo de estados anêmicos com alta suspeita de AI que não poderão ser classificados facilmente. Recentemente têm sido desenvolvidos imunoensaios para determinar hepcidina e citocinas inflamatórias, que poderão colaborar no futuro, para um diagnóstico certo. Existem atualmente modelos experimentais de AI em ratos que poderiam ser úteis para avaliar diferentes tratamentos. A este respeito, os inibidores de hepcidina e vários moduladores inflamatórios aparecem como terapias promissoras.

Sexual satisfaction in patients with cancer / Satisfacción sexual en enfermos de cáncer / Satisfação sexual em pacientes com câncer

Abstract This study aimed to compare the dimensions of sexual satisfaction in subjects with and without cancer. Independent variables were: different types of cancer, time elapsed since diagnosis, types of treatment and changes in body image. The dependent variable was level of satisfaction with sexual relations. The sample consisted of 184 participants, of whom 95 belonged to the cancer group (ages between 26 and 84 years) and 89 to the non-cancer group (ages between 19 and 67 years). The instrument used was the Sexual Satisfaction Questionnaire (QSRS, for its Portuguese acronym). The results showed significant differences between the cancer group and the non-cancer group. Individuals with a history of cancer disease had lower values (17.93 ± 9.67) at the level of sexual function compared to individuals with no history of the disease (30.19 ± 4.2). Individuals with cancer who had higher values of self-esteem were those with urological cancer (16.76 ± 2.85), followed by breast cancer (14.83 ± 3.34) and "other cancers" (14.41 ± 5.5), whereas those with digestive cancer presented the lowest values (5.68 ± 13.63). In sexual functioning, the group of "other cancers" showed the highest levels of satisfaction (23.53 ± 10.12), while people with breast cancer (19.54 ± 9.36), digestive cancer (18.50 ± 12.57), and urological cancer (29.12 ± 7.22) presented the lowest levels of satisfaction. Within the group of people with cancer, those who had less than one year and between three to five years of having been diagnosed reflected less satisfactory sexual performance values. On the other hand, radiation treatments, surgery and "other treatments" showed negative effects on sexual functioning, as well as changes in body image. All independent variables had a negative impact on sexual satisfaction and performance, with the exception of weight loss, vomiting, and hair loss.

Resumen Este estudio tuvo como objetivo comparar las dimensiones de satisfacción sexual en sujetos con y sin cáncer, específicamente al comparar los diferentes tipos de cáncer, el tiempo de diagnóstico y los tipos de tratamiento, con cambios en la imagen corporal y el nivel de satisfacción con las relaciones sexuales. La muestra estuvo compuesta por 184 participantes, de los cuales 95 pertenecieron al grupo con cáncer (edades entre los 26 y 84 años) y 89 al grupo sin cáncer (edades entre los 19 y 67 años). El instrumento utilizado fue el Questionário de Satisfação com o Relacionamento Sexual (QSRS). Los resultados mostraron diferencias significativas entre el grupo con cáncer y el grupo sin cáncer, los individuos con antecedentes de enfermedad de cáncer presentaron valores más bajos (17.93 ± 9.67) en el nivel de la función sexual en comparación con los individuos sin antecedentes de dicha enfermedad (30.19 ± 4.2). Los individuos con cáncer que presentaron valores más altos en autoestima fueron los de cáncer urológico (16.76 ± 2.85), seguidos por los de cáncer de mama (14.83 ± 3.34) y "otros tipos de cáncer" (14.41 ± 5.5); siendo los de cáncer digestivo quienes presentaron los valores más bajos (5.68 ± 13.63). En el funcionamiento sexual, el grupo de "otros tipos de cáncer" mostró niveles más altos de satisfacción (23.53 ± 10.12), mientras que las personas con cáncer de mama (19.54 ± 9.36), cáncer digestivo (18.50 ± 12.57) y cáncer urológico (29.12 ± 7.22) presentaron los niveles más bajos de satisfacción. Dentro del grupo de personas con cáncer, los que tienen menos de un año y de tres a cinco años después de haber tenido el diagnóstico reflejaron valores de funcionamiento sexual menos satisfactorios. Por otro lado, los tratamientos de radiación, cirugía y "otros tratamientos" mostraron efectos negativos en el funcionamiento sexual, así como cambios en la imagen corporal. Todas las variables independientes tuvieron un impacto negativo en la satisfacción y el desempeño sexual, con excepción de la pérdida de peso, el vómito y la pérdida de cabello. Palabras clave: Cáncer, sexualidad, funcionamiento sexual, enfermedad maligna.

Resumo O objetivo foi comparar indivíduos em função das seguintes variáveis independentes: cancro e sem cancro, diferentes tipos de cancro, tempo de diagnóstico, diferentes tipos de tratamento e mudanças na imagem corporal tendo por variável dependente o nível da satisfação da relação sexual. A amostra foi constituída por 184 participantes (95 com cancro com idades entre 26 e 84 anos; 89 sem cancro, com idades entre 19 e 67 anos). Foi utilizado o Questionário de Satisfação com o Relacionamento Sexual (QSRS). Verificaram-se efeitos significativos entre os indivíduos com historial de doença oncológica ao nível do funcionamento sexual, comparativamente com os indivíduos sem historial de doença oncológica. Indivíduos com cancro urológico apresentam valores mais elevados ao nível da autoestima (16.76 ± 2.85), seguidos pelo cancro de mama (14.83 ± 3.34) e outros tipos de cancro (14.41 ± 5.05). O cancro digestivo é o que apresenta os valores mais baixos (13.63 ± 5.68). Com relação ao funcionamento sexual, o grupo "outros tipos de cancro" apresenta maiores níveis de satisfação (23.53 ± 10.12). Seguem-se o cancro de mama (19.54 ± 9.36) e os digestivos (18.50 ± 12.57) e, por último, o cancro urológico, que apresenta os níveis mais baixos (12.29 ± 7.22). Dentro do grupo de indivíduos com cancro, o período inferior a um ano e de três a cinco anos apresenta valores menos satisfatórios na dimensão funcionamento sexual, e os tratamentos de radioterapia, cirurgia e "outros tipos de tratamento" produzem efeitos negativos ao nível do funcionamento sexual, assim como as mudanças na imagem corporal. No presente estudo, com a exceção de perda de peso, vómitos e perda de cabelos, todas as variáveis independentes têm um impacto negativo na satisfação/desempenho sexual.

Paniculitis citofágica histiocítica asociada a leucemia mieloide crónica / Cytophagic histiocytic panniculitis associated with acute myeloid leukemia

La paniculitis citofágica histiocítica es una rara alteración mediada inmunitariamente, que puede tener un curso indolente o ser fatal cuando se acompaña de síndrome hemofagocítico. Presentamos el caso de una mujer con paniculitis citofágica histiocítica asociada a leucemia mieloide aguda.

Hemosiderotic fibrohistiocytic lipomatous lesion: case report and review of the literature / Lesão lipomatosa fibrohistiocítica hemossiderótica: relato de caso e revisão da literatura

CONTEXT: Lesions of the adipose tissue are the most common type of soft-tissue lesion among adults. CASE REPORT: We describe the case of a 33-year-old female patient with a soft-tissue lesion in her left knee that was diagnosed as a hemosiderotic fibrohistiocytic lipomatous lesion. This type of lesion, which was described for the first time in 2000, preferentially affects the ankle region of middle-aged women with a history of previous local trauma. Lesion recurrence is common, caused by incomplete resection, although there have not yet been any reports of metastases. After a review of the literature, we describe the clinical, radiological, morphological and immunohistochemical characteristics, along with their main differential diagnoses.

CONTEXTO: Lesões de tecido adiposo são as mais comuns de partes moles em adultos. RELATO DE CASO: Descrevemos o caso de uma paciente do sexo feminino, 33 anos, com lesão em partes moles do joelho esquerdo diagnosticada como lesão lipomatosa fibrohistiocítica hemossiderótica. Essa lesão foi descrita pela primeira vez em 2000, acometendo preferencialmente a região do tornozelo de mulheres de meia-idade com história de trauma prévio local. Recidiva da lesão é comum devido à ressecção incompleta e não há até o momento relato de metástase. Após revisão da literatura, descrevemos as características clínicas, radiológicas, morfológicas, imunoistoquímicas assim como seus principais diagnósticos diferenciais.

Characterization of the Proliferated Histiocytes in Acute Leukemia by Performing Immunohistochemistry

BACKGROUND: The bone marrow biopsy sections of acute leukemia patients occasionally reveal a proliferation of large mononuclear cells that accompany the leukemic blasts, and this proliferation shows a starry sky pattern. We characterized these large mononuclear cells by performing immunohistochemistry with 12 different antibodies. The clinical characteristics were examined and then we determined their difference from hemophagocytic lymphohistiocytosis (HLH) and malignant histiocytic disorders. METHODS: Of the 200 acute leukemic bone marrow biopsy samples, 11 ALL and 10 AML cases showed large mononuclear cell proliferations. The panel of antibodies used for immunohistochemistry included those against the mononuclear phagocyte system, and immunohistochemistry was performed on the patients' initial specimens and the complete remission specimens. 10 normal specimens, 4 initial CML specimens and their complete hematologic response specimens were included as controls. RESULTS: The large mononuclear cells showed immunohistochemical results consistent with histiocytes. They were negative for the markers of dendritic cells the histiocytes and cytokines that are involved in the pathogenesis of HLH and vascular proliferation. Histiocyte proliferation was not observed in the complete remission specimens and in the initial and complete hematological response specimens of the CML patients and the normal bone marrow specimens. None of the cases fulfilled the criteria of HLH, and all 5 ALL cases, for which the immunophenotype results were available, showed a B cell phenotype. CONCLUSION: We characterized the large mononuclear cell proliferations as reactive histiocyte proliferations and we differentiated these from those of secondary HLH and malignant histiocytic disorders. A proportion of the large mononuclear cells showed negative results for all 12 antibodies and they showed characteristics that were suggestive of small fat cells. The pathophysiology and the prognostic effect of the reactive histiocyte proliferation accompanying acute leukemia require further study.

Fibrohistiocitoma maligno / Malignant fibrous histiocytoma

El fibrohistiocitoma maligno ha sido considerado el sarcoma de los tejidos blandos más común, durante la adultez media y tardía. Es frecuente en tejidos profundos y músculo estriado, y raro como tumor cutáneo. Reportamos el caso de un varón de 31 años, con una lesión tumoral de seis meses en piel de la zona iliaca derecha, que muestra en el estudio histopatológico un fuerte infiltrado de células neoplásicas indiferenciadas, diagnosticándose fibrohistiocitoma maligno, y detectándose signos de metástasis ósea. Se remarca la utilidad del estudio inmunohistoquímico para la tipificación de tumores con células neoplásicas indiferenciadas.

Expression of Matrix Metalloproteinase-9 Correlates with Poor Prognosis in Human Malignant Fibrous Histiocytoma / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: 92 kDa matrix metalloproteinase-9 (MMP-9) is believed to play an important role in degrading the matrix and basement membrane, contributing to the invasion and metastasis of malignant solid tumors. However, little is known about its involvement in a malignant fibrous histiocytoma. The aim of this study was to investigate the expression of MMP-9 and to correlate its expression with clinicopathologic parameters in human malignant fibrous histiocytomas. MATERIALS AND METHODS: Archival tumor tissues from 20 patients with a malignant fibrous histiocytoma were analyzed by immunohistochemistry for the expression of MMP-9. Clinical information was obtained through the computerized retrospective database from the tumorregistry. RESULTS: Seventeen of 20 (85%) tumors showed a positive reaction for MMP-9. MMP-9 activity was inversely correlated with patients' survival time (p=.011). There was no significant correlation between the activated MMP-9 expression and all the other clinicopathologic variables. CONCLUSION: Our data demonstrate that MMP-9 activation is likely to occur in human malignant fibrous histiocytomas. It is also noteworthy that the expression of MMP-9 may aid in predicting patients' poor prognosis.

A Case with Disseminated Macrophage-related Histiocytic Sarcoma Diagnosed by Positive Histiocytic Markers / 대한혈액학회지

Malignant histiocytosis (MH) is characterized by an invasive, progressive proliferation of neoplastic histiocytes associated with jaundice, lymphadenopathy, refractory anemia, leukopenia, and often hepatic and splenic enlargement. As lymphoblastic leukemia and lymphoma are regarded as neoplasms of lymphoid cells, MH is thought to represent a malignant transformation of the macrophage and dendritic cells. A classification of malignant histiocytic disorders was oriented by cell lineage in the Histiocyte Society's 1987 version. So dendritic cell-related histiocytic sarcoma (localized or disseminated) and macrophage-related histiocytic sarcoma (localized or disseminated) are the recommended nosology. To establish the correct diagnosis, the major challenge seems to distinguish lymphoid from histiocytic cells. M-CSF receptor, lysozyme, Ki-M8, and S-100 protein, etc are useful markers for histiocytes and T-cell and B-cell lineage markers, such as CD3, CD20, and CD79, etc, for lymphocytes. We have experienced a patient with disseminated histiocytic sarcoma diagnosed by positive istiocytic markers, such as lysozyme, S-100 protein, and CD68.

Conjugate formation between effector and target as a function of cytotoxicity in antibody-dependent killing of AK-5 tumor.

The present study was carried out to mechanistically view a possible correlation between the process of, conjugate formation and its relation to target cell death. AK-5 killing is mediated by CD8+ natural killer cells through ADCC. Immune effectors on exposure to antibody primed AK-5 tumor cells formed tight conjugates. Ability of various cell types (NK, T, monocytes and macrophages) to form conjugates was evaluated. Marked increase in the number of NK cells binding to the target as compared to the other cell types was observed. Cytotoxicity of free and bound effectors against antibody tagged AK-5 cells demonstrated a reduced cytotoxic ability of the former in contrast to a significantly high lytic potential of the bound effectors. The results highlight the requirement for priming of NK cells which mediate killing of AK-5 tumor and provide additional evidence that formation of stable conjugates acts as the first signal for triggering lymphocyte activation and effective target cell lysis.